Examining Additional PROs from BE COMPLETE and BE OPTIMAL

EP: 1.Background on PROs in Psoriatic Arthritis

EP: 2.Common Symptoms and Treatments in Psoriatic Arthritis

EP: 3.Treatment Selection for Psoriatic Arthritis

EP: 4.Key Differences in Inclusion Criteria Between BE OPTIMAL and BE COMPLETE

EP: 5.Baseline Characteristics and Alignment to Clinical Practice

EP: 6.Analyzing Pain and Fatigue Outcomes

Now Viewing

EP: 7.Examining Additional PROs from BE COMPLETE and BE OPTIMAL

Multiple validated quality of life instruments demonstrated consistent improvement patterns with bimekizumab treatment across different measurement domains. The PsAID-12 questionnaire, developed by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis with extensive patient input, combines functional assessment with quality-of-life evaluation and showed significant improvement in bimekizumab-treated patients. The Psoriatic Arthritis Quality of Life measure provided additional validation of treatment benefits, whereas the BASDAI, originally developed for ankylosing spondylitis but widely used across spondyloarthritis trials, confirmed improvement across the broader spondyloarthritis spectrum.

Work productivity assessment through the Work Productivity and Activity Index revealed significant treatment benefits in absenteeism (missing entire workdays) and presenteeism (reduced work capacity while present). Dr. Mease emphasized that presenteeism often represents a more significant problem than complete work absence, as patients may force themselves to attend work for financial reasons while experiencing substantial performance reduction throughout the day. The “drag during the day” significantly impacts individual productivity and overall workplace effectiveness, making this metric particularly relevant for understanding treatment value.

The comprehensive improvement across multiple patient-reported outcome (PRO) measures demonstrates bimekizumab’s ability to address the holistic disease burden beyond traditional clinical metrics. These quality-of-life improvements translate to meaningful real-world benefits, including preserved workforce participation, reduced reliance on disability programs, and enhanced ability to fulfill family and professional responsibilities. The consistent positive outcomes across diverse measurement tools provide robust evidence that effective inflammatory control translates to genuine improvements in the aspects of health and function that matter most to patients living with psoriatic arthritis.